● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.51 for the 2020 fiscal year.
● Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
● The company does not generate enough profits, which is an alarming weak point.
● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
● The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
● For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.